| Literature DB >> 27867340 |
Jean-Maurice Delabar1, Bernadette Allinquant2, Diana Bianchi3, Tom Blumenthal4, Alain Dekker5, Jamie Edgin6, John O'Bryan7, Mara Dierssen8, Marie-Claude Potier9, Frances Wiseman10, Faycal Guedj3, Nicole Créau1, Roger Reeves11, Katheleen Gardiner12, Jorge Busciglio13.
Abstract
Down syndrome (DS) is the most common genetic cause of intellectual disability (ID) in humans with an incidence of ∼1:1,000 live births worldwide. It is caused by the presence of an extra copy of all or a segment of the long arm of human chromosome 21 (trisomy 21). People with DS present with a constellation of phenotypic alterations involving most organs and organ systems. ID is present in all people with DS, albeit with variable severity. DS is also the most frequent genetic cause of Alzheimer's disease (AD), and ∼50% of those with DS will develop AD-related dementia. In the last few years, significant progress has been made in understanding the crucial genotype-phenotype relationships in DS, in identifying the alterations in molecular pathways leading to the various clinical conditions present in DS, and in preclinical evaluations of potential therapies to improve the overall health and well-being of individuals with DS. In June 2015, 230 scientists, advocates, patients, and family members met in Paris for the 1st International Conference of the Trisomy 21 Research Society. Here, we report some of the most relevant presentations that took place during the meeting.Entities:
Keywords: Down Syndrome; Trisomy 21 Research Society
Year: 2016 PMID: 27867340 PMCID: PMC5109983 DOI: 10.1159/000449049
Source DB: PubMed Journal: Mol Syndromol ISSN: 1661-8769